

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6966235

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NORTIC HOLDINGS INC.	08/27/2021
RECEIVING PARTY DATA	
Name:	GRACE THERAPEUTICS INC.
Street Address:	675 US HIGHWAY 1
City:	NEW BRUSWICK
State/Country:	NEW JERSEY
Postal Code:	08902
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	10092557
Patent Number:	10092553
Patent Number:	10799486
Patent Number:	10765671
Application Number:	15360644
Application Number:	15360676
Application Number:	15404859
Application Number:	17011345
Application Number:	17014276
Application Number:	16281676
Application Number:	16703444
CORRESPONDENCE DATA	
Fax Number:	(514)286-5474
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5148474747
Email:	sheri.vandray@nortonrosefulbright.com
Correspondent Name:	NORTON ROSE FULBRIGHT CANADA LLP
Address Line 1:	1 PLACE VILLE MARIE
Address Line 2:	SUITE 2500
Address Line 4:	MONTREAL, CANADA H3B 1R1

PATENT

ATTORNEY DOCKET NUMBER:	55494581-GEN-MTL
NAME OF SUBMITTER:	DEMIAN BARBAS
SIGNATURE:	/DEMIAN BARBAS/
DATE SIGNED:	10/13/2021
Total Attachments: 6 source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page1.tif source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page2.tif source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page3.tif source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page4.tif source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page5.tif source=PatentAssignmentAgreementNORTICOLDINGSINCtoGRACETHERAPEUTICSINC#page6.tif	

Patent Assignment Agreement

PATENT ASSIGNMENT

This Patent Assignment (this "**Patent Assignment**"), dated as of August 27, 2021 (the "**Effective Date**"), is entered into by and between Nortic Holdings Inc., a Delaware corporation, with a place of business at 2 Tower Center Boulevard, Suite 1101G, East Brunswick, NJ 08816 ("**Assignor**"), and Grace Therapeutics Inc., a Delaware corporation, with a place of business at 675 US Highway 1, New Brunswick, NJ 08902 ("**Assignee**").

WHEREAS, the Assignor is the owner of the patents and patent applications described on **Schedule 1** hereto (the "**Patents**"); and

WHEREAS, pursuant to the terms of that certain Intellectual Property Asset Purchase Agreement, ("**APA**"), by and among Assignors and Assignee, dated and effective as of August 27, 2021, Assignors have agreed to assign to Assignee all of Assignors' Intellectual Property relating to the Patents. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings assigned to such terms in the APA.

NOW THEREFORE, for the consideration set forth in the APA and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as of the Effective Date, Assignor hereby sells, transfers, and assigns to Assignee, and its successors and assigns, Assignor's entire right, title, and interest in the Patents, including all reissues, divisions, reexaminations, renewals, extensions, provisionals, substitutions, continuations and continuations-in-part thereof, and all equivalent or similar rights anywhere in the world in inventions and discoveries first disclosed in such Patents therefor, together with all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights with respect to the Patents, including causes of action and other enforcement rights for (a) damages, (b) injunctive relief, and (c) any other remedies of any kind, and in each case for past, current, and future infringement, misuse, or misappropriation of any such Patents, including royalties and other payments.

Assignor hereby authorizes the respective patent office (e.g., US Patent and Trademark Office or its foreign counterparts) or Governmental Authority in each applicable jurisdiction to issue any and all patents, certificates of invention or other similar governmental grants or issuances that may be granted for any of the Patents in the name of Assignee, as the assignee.


This Patent Assignment is governed by and construed in accordance with the internal laws of the State of New Jersey without giving effect to any choice or conflict of law provision or rule that would require or permit the application of the laws of any jurisdiction other than those of the State of New Jersey. Any legal suit, action, or proceeding arising out of or related to this Patent Assignment or the licenses granted hereunder may be instituted in the federal courts of the United States or the courts of the State of New Jersey in each case located in New Jersey, and each party irrevocably submits to the jurisdiction of such courts in any such suit, action, or proceeding. The parties hereto agree that irreparable damage would occur if any provision of this Patent Assignment were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.

This Patent Assignment shall enure to the benefit of and be binding upon Assignee and Assignor and their respective successors and assigns. This Patent Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Patent Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Patent Assignment.

[Signature Page Follows]

IN WITNESS WHEREOF, each of the undersigned has caused this Patent Assignment to be executed and delivered by its duly authorized representative as of the Effective Date.

ASSIGNOR:
NORTIC HOLDINGS INC.

By:  _____

Name: Vimal Kavuru

Title: CEO

ASSIGNEE:
GRACE THERAPEUTICS INC.

By: _____

Name: _____

Title: _____

IN WITNESS WHEREOF, each of the undersigned has caused this Patent Assignment to be executed and delivered by its duly authorized representative as of the Effective Date.


ASSIGNOR:
NORTIC HOLDINGS INC.

By: _____

Name: _____

Title: _____

ASSIGNEE:
GRACE THERAPEUTICS INC.

By:  _____
FCEAAF62A7A2497...

Name: George Kottayil

Title: CEO

Schedule I

Patents

GTX-101

Title: Topical Film-Forming Spray

Inventors: Kottavil, George S.; Kumar, Amresh; Sunthakar, Prasanna; Kavuru, Vimal

Australia - Patent Application No. 2016359706 filed November 23, 2016 (pending)

Canada – Patent Application No. 3005150 filed November 23, 2016 (pending)

China – Patent Application No. 201680079483.6 filed November 23, 2016 (pending)

Europe (EPO) - Patent Application No. 6869283.8 filed November 23, 2016 (Allowed)

Hong Kong – Patent Application No. 19120894.1 filed November 23, 2016 (pending)

India – Patent Application No. P00201804231 filed November 23, 2016 (pending)

Japan – Patent Application No. 2018-546405 filed November 23, 2016 (pending)

Republic of Korea (South Korea) – Patent Application No. 10-2018-7017229 filed November 23, 2016 (pending)

Mexico – Patent Application No. MX/a/2018/006302 filed November 23, 2016 (pending)

South Africa – Patent No. 2018/04162 filed November 23, 2016 (granted)

United States – Patent Application No. 15/360644 filed November 23, 2016 which claims priority from US Provisional Application No. 62/258672 filed November 23, 2015; published as US 2017/0296484 on October 19, 2017 (pending)

United States – Patent Application No. 15/360676 filed November 23, 2016 which claims priority from US Provisional Application No. 62/258672 filed November 23, 2015; published as US 2017/0296484 on October 19, 2017 (pending)

GTX-102

Title: Betamethasone Oral Spray Formulation and Method of Use to Treat Ataxia

Inventors: Kottavil, George S. . Kumar, Amresh; Sunthakar, Prasanna; Kavuru, Vimal

Australia – Patent Application No. 2017249396 filed April 12, 2017; published (pending)

Canada – Patent Application No. 3011015 filed April 12, 2017; published (pending)

Europe (EPO) – Patent Application No. 17738920.2 filed April 12, 2017; published November 28, 2018 (pending)

Hong Kong – Patent Application No. 18116144.1 filed April January 12, 2017; published (pending)

Japan – Patent Application No. 2018-555443 filed April 12, 2017 (Granted)

United States – Patent Application No. 15/404859 filed January 12, 2017 which claims priority from US Provisional Application No. 62/277707 filed January 12, 2016; published as US 2017-0196889 (pending)

GTX-104

Title: Stable Nimodipine Parenteral Formulation

Inventors: Kottayil, George S.; Kumar, Amresh; Sunthankar, Prasanna; Kavuru, Vimal

Australia – Patent Application No. 2020201863 filed March 13, 2020 (divisional of application 2017249396 filed April 12, 2017) – (pending)

Canada – Patent Application No. 3021237 filed April 12, 2017; published (pending)

China – Patent Application No. 2017800276329 April 12, 2017; (pending)

Eurasia – Patent Application No. 201891977 filed April 12, 2017; published (pending)

Europe (EPO) – Patent Application No. 17783039.5 filed November 23, 2016; published (pending)

Hong Kong – Patent Application No. 19128295.3 filed November 23, 2016; published (pending)

India – Patent Application No. 201847042493 filed November 23, 2016; published (pending)

Israel – Patent Application No. 262335 filed April 12, 2017; published (pending)

Japan – Patent Application No. 2020-160951 filed June 25, 2020 (divisional of Application No. 2018-553182 filed April 12, 2017); (pending)

Republic of Korea (South Korea) – Patent Application No. 10-2018-7032646 filed April 12, 2017, 2016 (pending)

New Zealand – Patent Application No. 747237 filed April 12, 2017 (pending)

United States – Patent No. 10092557 (Application No. 15/485813) filed April 12, 2017 and published as US 2017-0296527, which claims priority from US Provisional Application No. 62/322008 filed April 13, 2016; (granted)

United States – Patent No. 10092553 (Application No. 15/638901) filed June 30, 2017 and published as US 2017-0296522, which is a continuation-in-part of Application No. 15/485813 filed April 12, 2017, which claims priority from US Provisional Application No. 62/322008 filed April 13, 2016); (granted)

United States – Patent No. 10799486 (Application No. 16/046487) filed July 26, 2018 (continuation of Application No. 15/638901 filed June 30, 2017 and published as US 2018-0325882, which is a continuation of Application No. 15/485813 filed April 12, 2017), which claims priority from provisional Application 62/322,008, filed April 13, 2016); (granted)

United States – Patent No. 10765671 (Application No. 16/046676) filed July 26, 2018 (continuation of Application No. 15/485813 filed April 12, 2017 and published as US 2018-0325886 which claims priority from provisional Application 62/322,008, filed April 13, 2016); (granted)

United States – Patent Application No. 17/011345 filed September 8, 2020 (continuation-in-part of Application No. 16/046487 filed July 26, 2018 which is a continuation of Application No. 15/638,901 filed June 30, 2017 which is a continuation-in-part of Application No. 15/485813 filed April 12, 2017); published as US 2020-0397773 (pending)

United States – Patent Application No. 17/014276 filed September 3, 2020 (continuation of Application No. 16/046487 which is a continuation of Application No. 15/485813 filed April 12, 2017); published as US 2020-0397769 (pending)

GTX-104 (Nimodipine Alcohol-Free Composition)

Title: Stable Nimodipine Parenteral Formulation

Inventors: Inventors: Kottavil, George S.; Kumar, Amresh; Sunthankar, Prasanna; Kavuru, Vimal

Japan – Patent Application No. 2020-544248, filed February 21, 2019; pending

Europe (EPO) – Patent Application No. 19757204.3 filed February 21, 2019; published (pending)

Patent Cooperation Treaty (PCT) – Patent Application No. PCT/US2019/018945 filed on February 21, 2019 (claims priority from US Provisional Application No. 62/633863 filed February 22, 2018); published as WO 2019/165066 on August 29, 2019 (pending)

United States – Patent Application No. 16/281676 filed February 21, 2019 (claims priority from US Provisional Application No. 62/633863 filed February 22, 2018); published as US2019/0255033 on August 22, 2019

GTX-201

Title: Therapeutic Composition of Intranasal Lidocaine

Inventors: Kottavil, George S.

Patent Cooperation Treaty (PCT) – Patent Application No. PCT/US2019/064472 filed on December 4, 2019; published as WO 2020/131380 on June 25, 2020 (pending)

United States – Patent Application No. 16/703444 filed December 4, 2019 (claims priority from US Provisional Application No. 62/781969 filed December 19, 2018); published as US 2020/0197338 (pending)